+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027

  • PDF Icon

    Report

  • 298 Pages
  • July 2022
  • Region: Global
  • Arizton
  • ID: 5639215
UP TO OFF until Aug 31st 2022
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The global genital herpes treatment market is expected to grow at a CAGR of 3.76% during 2022-2028

Herpes simplex virus (HSV), also known as herpes, is a widespread infection worldwide. HSV-1 causes infection in or around the mouth (oral herpes), but it can also cause genital herpes. Herpes simplex virus type 2 (HSV-2) causes genital herpes, a dangerous sexually transmitted infection (STI). The genitals of those who have genital herpes develop painful blisters. Blisters can form on the anus or inside it. Oral and vaginal herpes is usually asymptomatic or unnoticed, but they can cause painful blisters or ulcers at the injection site, ranging from mild to severe. The infection is permanent, and symptoms might repeat for years.

The World Health Organization estimates that 20% of people living with HIV / AIDS are in their 20s and that 1 in 20 adolescents get STI each year. Adolescents are more likely to engage in unprotected sex, have multiple sexual partners, and engage in transgenerational transactional sex. The cervical lining in female adults and young women makes them more susceptible to STIs. According to the CDC, roughly 20% of the U.S. population - approximately one out of every five people in the U.S. had an STI on any given day in 2018; October 13 is National Herpes Awareness Day, an excellent opportunity to raise awareness about the causes and treatment of various types of herpes contaminations, particularly genital herpes. The disease and treatment searches are increasing with the high internet penetration around the globe. Young adults are giving more time to internet browsing. They frequently search about the treatment methods for STIs and their prevention. MSM are vulnerable demographics to spreading STIs. While anyone who has sex can get an STD, the sexually active LGBT population, including gay, bisexual, and MSM, are at greater risk. In addition to getting higher rates of HSV, more than half of all new HIV infections happen among MSM. Many aspects contribute to the higher rates of STIs among LGBT.

Promising Investigational Therapies for Treating Genital Herpes

  • Researchers have been working on the development of herpes vaccines for decades. Several clinical trials have been conducted to test therapeutic (to reduce recurrence and viral shedding in people already infected with HSV) and prophylactic (to prevent infection) drug candidates.
  • mRNA-1608 a Moderna's HSV vaccine candidate is a vaccine candidate against HSV-2 infection. Moderna believes that an HSV-2 vaccine could provide cross-protection against HSV-1. With mRNA-1608, the Company intends to bring a strong antibody reaction with neutralizing and effector functionality shared with cell-mediated immunity.
  • HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and other critical Genital Herpes pipeline medicines are in various stages of clinical trials for the treatment of Genital Herpes.
  • Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg ImmunoTherapeutics, AiCuris, and United Biopharma are some of the most well-known pharmaceutical companies active in the field.
  • X-Vax Technology announced in May 2021 that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental herpes simplex virus 1 and 2 vaccines (HSV-1 and -2).
  • The FDA granted AiCuris Breakthrough Therapy Designation for Pritelivir to treat HSV infections in immunocompromised patients in June 2020.

Increasing Demand for Genital Herpes Treatment by Homosexuals

  • Homosexual acceptance increased by double digits between 2002 and 2019. This includes a 21-point increase in South Africa since 2002 and a 19-point increase in South Korea over the same period. India has also seen a rise of 22 points since 2014.
  • MSM groups are at increased risk of HIV and other STIs due to sexual networks, the number of concurrent partners, and behavioral or biological factors such as condom-less sex, anal sex, drug use, etc.
  • MSM are vulnerable demographics to spreading STIs. While anyone having sex can get an STD, the sexually active LGBT population, including gay, bisexual, and MSM, are at greater risk.
  • In addition to getting higher rates of HSV, more than half of all new HIV infections happen among MSM. Many aspects contribute to the higher rates of STIs among MSM.

Growing Burden of Sexually Transmitted Diseases

  • As the latest data from WHO, an expected 3.7 billion individuals younger than 50, or 67% of the populace, in 2016 had HSV-1 contamination (oral or genital). The assessed predominance of the contamination was most elevated in Africa (88%) and least in the Americas (45%).
  • Genital herpes caused by HSV-2 is a global problem. According to WHO data published in 2022, an estimated 491 million (13%) aged 15-49 years suffered from infections worldwide in 2016. More women than men are infected with HSV-2. In 2016, an estimated 313 million women and 178 million men lived with the infection. This is because male-to-female sexually transmitted HSV is more efficient than female-to-male sexual transmission.
  • Genital herpes is a worldwide issue, and an expected 491 million (around 13%) individuals between 15 and 49 years suffer from this STD. In 2016, around 313 million women and 178 million men had genital herpes. This is because sexual transmission of HSV is more proficient from men to ladies than from ladies to men. The pervasiveness of HSV-2 disease was assessed to be most noteworthy in Africa (44% in ladies and 25% in men), trailed by the Americas (24% in ladies and 12% in men). 

MARKET SEGMENTATION ANALYSIS


The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.

The Acyclovir segment reported a significant share of around 50.44% among all drug types. The Acyclovir is the leading segment due to availability in all three major routes of administration. The key player in the genital herpes treatment GSK has the branded drug Zovirax. Acyclovir is the oldest drug in the antiviral category and has many generic versions of Zovirax available on the market.

The Retail pharmacies segment reported a significant share of around 49.79% among all distribution channels. The retail pharmacy segment is showing the highest share due to the availability of branded and generic versions of all antiviral drugs in retail pharmacies. People who have genital herpes is most referred to go to nearby retail pharmacy outlet for anti-genital herpes treatment because of the stigma related to sexually transmitted diseases.

The HSV-2 segment reported a major share of around 84.10% among all virus types. HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes. According to WHO data published in 2022, an estimated 491 million (13%) aged 15-49 years were suffering from infections worldwide in 2016. More women than men are infected with HSV-2.

Among all routes of administration, the oral segment reported a major share of around 64.03%. Mostly all the anti-genital herpes drugs are available in an oral formulation. Chronic suppressive doses of oral antivirals, including Acyclovir (Zovirax), valacyclovir (Valtrex), and famciclovir, have significantly reduced the incidence of clinical recurrence and the rate of asymptomatic excretion. Oral administration of Acyclovir effectively suppresses recurrent genital herpes. Daily administration of Acyclovir reduces the recurrence rate by up to 80%, and 25-30% of patients have no further recurrence while taking the drug.

Segmentation by Drug Type

  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Other Drugs

Segmentation by Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Segmentation by Virus Type

  • HSV-2
  • HSV-1

Segmentation by Route of Administration:

  • Oral
  • Topical
  • Injection

GEOGRAPHIC ANALYSIS


North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%. In North America, the US is the key revenue contributor mainly due to an increase in the demand for genital herpes drugs reflecting the growing awareness of various antiviral drugs and their benefits against different STIs, including genital herpes. Europe is the second-largest regional market and is witnessing steady growth owing to increasing acceptance of both branded and OTC antiviral drugs for treating genital herpes. However, APAC is likely to see faster growth than all other regions. Around 1 in every ten people in APAC are infected with HSV-2, which majorly causes genital herpes. The APAC region is witnessing high demand for off-label, generic, and OTC drugs for treating genital herpes. The region has many regional and local vendors offering generic and OTC antiviral drugs, which are majorly used for treating genital herpes.

Segmentation by Region

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • APAC
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Turkey
  • Saudi Arabia

Key Vendors

  • GlaxoSmithKline
  • Glenmark pharmaceuticals
  • Viatris
  • Novartis
  • Teva Pharmaceuticals
  • Bausch Health Companies

Other Prominent Vendors

  • Reddy's Laboratories
  • Cipla
  • Pfizer
  • Eli Lilly & Company
  • Avet Pharmaceuticals
  • Aurobindo Pharma
  • Centurion Remedies
  • Abbott
  • Macleods Pharmaceuticals
  • FDC
  • Hetero
  • Zydus Group
  • Torrent Pharma
  • Finecure Pharmaceuticals
  • ADLEY FORMULATIONS
  • Medico Remedies
  • Zeelab Pharmacy

KEY QUESTIONS ANSWERED


1. HOW BIG IS THE GLOBAL GENITAL HERPES TREATMENT MARKET?
2. WHAT IS THE GROWTH RATE OF THE GLOBAL GENITAL HERPES TREATMENT MARKET?
3. WHO ARE THE KEY PLAYERS IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
4. WHAT ARE THE LATEST TRENDS & OPPORTUNITIES IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
5. WHICH REGION HOLDS THE LARGEST SHARE IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?

Table of Contents

1 Research Methodology2 Research Objectives3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.1.3 Market Estimation Caveats
4.2 Base Year
4.3 Scope of the Study
4.3.1 Market Segmentation by Drug Type
4.3.2 Market Segmentation by Distribution Channel
4.3.3 Market Segmentation by Virus Type
4.3.4 Market Segmentation by Route of Administration
4.3.5 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.1.1 Sti Control Health Policy Agenda
7.1.2 Global Prevalence of Hsv Infections
7.1.3 Risk of Hiv and Genital Herpes Among the Lgbtq+ Community
8 Market Opportunities & Trends
8.1 R&D of Genital Herpes Vaccine Candidates
8.2 Rise in Genital Herpes Cases in Lgbtq+ Community
8.3 Market Growth Potential in Low-Middle-Income Countries
8.4 Increased Online Purchase of Genital Herpes Therapeutics
9 Market Growth Enablers
9.1 Increased Burden of Stds
9.2 Awareness of Stis
9.3 Demand for Topical Genital Herpes Treatment Drugs
10 Market Restraints
10.1 Social Stigma Associated With Stds
10.2 Side Effects & Adverse Reactions to Genital Herpes Medications
10.2.1 Risks Associated With Valacyclovir
10.3 Limitations of Genital Herpes Treatment Medications
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry
12 Drug Type
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Acyclovir
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 Acyclovir: Geography Segmentation
12.4 Valacyclovir
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.4.3 Valacyclovir: Geography Segmentation
12.5 Famciclovir
12.5.1 Market Overview
12.5.2 Market Size & Forecast
12.5.3 Famciclovir: Geography Segmentation
12.6 Other Drugs
12.6.1 Market Overview
12.6.2 Market Size & Forecast
12.6.3 Other Drugs: Geography Segmentation
13 Distribution Channel
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Retail Pharmacies
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.3.3 Retail Pharmacies: Geography Segmentation
13.4 Hospital Pharmacies
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.4.3 Hospital Pharmacies: Geography Segmentation
13.5 Online Pharmacies
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.5.3 Online Pharmacies: Geography Segmentation
14 Virus Type
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hsv-2
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.3.3 Hsv-2: Geography Segmentation
14.4 Hsv-1
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.4.3 Hsv-1: Geography Segmentation
15 Route of Administration
15.1 Market Snapshot & Growth Engine
15.2 Market Overview
15.3 Oral
15.3.1 Market Overview
15.3.2 Market Size & Forecast
15.3.3 Oral: Geography Segmentation
15.4 Topical
15.4.1 Market Overview
15.4.2 Market Size & Forecast
15.4.3 Topical: Geography Segmentation
15.5 Injection
15.5.1 Market Overview
15.5.2 Market Size & Forecast
15.5.3 Injection: Geography Segmentation
16 Geography
16.1 Market Snapshot & Growth Engine
16.2 Geographic Overview
17 North America
17.1 Market Overview
17.2 Market Size & Forecast
17.2.1 North America: Drug Type Segmentation
17.2.2 North America: Distribution Channel Segmentation
17.2.3 North America: Virus Type Segmentation
17.2.4 North America: Route of Administration Segmentation
17.3 Key Countries
17.3.1 Us: Market Size & Forecast
17.3.2 Canada: Market Size & Forecast
18 Europe
18.1 Market Overview
18.2 Market Size & Forecast
18.2.1 Europe: Drug Type Segmentation
18.2.2 Europe: Distribution Channel Segmentation
18.2.3 Europe: Virus Type Segmentation
18.2.4 Europe: Route of Administration Segmentation
18.3 Key Countries
18.3.1 Germany: Market Size & Forecast
18.3.2 France: Market Size & Forecast
18.3.3 Uk: Market Size & Forecast
18.3.4 Italy: Market Size & Forecast
18.3.5 Spain: Market Size & Forecast
19 Apac
19.1 Market Overview
19.2 Market Size & Forecast
19.2.1 Apac: Drug Type Segmentation
19.2.2 Apac: Distribution Channel Segmentation
19.2.3 Apac: Virus Type Segmentation
19.2.4 Apac: Route of Administration Segmentation
19.3 Key Countries
19.3.1 China: Market Size & Forecast
19.3.2 Japan: Market Size & Forecast
19.3.3 India: Market Size & Forecast
19.3.4 South Korea: Market Size & Forecast
19.3.5 Australia: Market Size & Forecast
20 Latin America
20.1 Market Overview
20.2 Market Size & Forecast
20.2.1 Latin America: Drug Type Segmentation
20.2.2 Latin America: Distribution Channel Segmentation
20.2.3 Latin America: Virus Type Segmentation
20.2.4 Latin America: Route of Administration Segmentation
20.3 Key Countries
20.3.1 Brazil: Market Size & Forecast
20.3.2 Mexico: Market Size & Forecast
20.3.3 Argentina: Market Size & Forecast
21 Middle East & Africa
21.1 Market Overview
21.2 Market Size & Forecast
21.2.1 Mea: Drug Type Segmentation
21.2.2 Mea: Distribution Channel Segmentation
21.2.3 Mea: Virus Type Segmentation
21.2.4 Mea: Route of Administration Segmentation
21.3 Key Countries
21.3.1 South Africa: Market Size & Forecast
21.3.2 Turkey: Market Size & Forecast
21.3.3 Saudi Arabia: Market Size & Forecast
22 Competitive Landscape
22.1 Competition Overview
22.2 Market Share Analysis
23 Key Company Profiles
23.1 GlaxoSmithKline
23.1.1 Business Overview
23.1.2 GlaxoSmithKline in Global Genital Herpes Treatment Market
23.1.3 Product Offerings
23.1.4 Key Strategies
23.1.5 Key Strengths
23.1.6 Key Opportunities
23.2 Glenmark Pharmaceuticals
23.2.1 Business Overview
23.2.2 Glenmark Pharmaceuticals in Global Genital Herpes Treatment Market
23.2.3 Product Offerings
23.2.4 Key Strategies
23.2.5 Key Strengths
23.2.6 Key Opportunities
23.3 Viatris
23.3.1 Business Overview
23.3.2 Viatris in Global Genital Herpes Treatment Market
23.3.3 Product Offerings
23.3.4 Key Strategies
23.3.5 Key Strengths
23.3.6 Key Opportunity
23.4 Novartis AG
23.4.1 Business Overview
23.4.2 Novartis AG in Global Genital Herpes Treatment Market
23.4.3 Product Offerings
23.4.4 Key Strategies
23.4.5 Key Strengths
23.4.6 Key Opportunities
23.5 Teva Pharmaceuticals
23.5.1 Business Overview
23.5.2 Teva Pharmaceuticals in Global Genital Herpes Treatment Market
23.5.3 Product Offerings
23.5.4 Key Strategies
23.5.5 Key Strengths
23.5.6 Key Opportunities
23.6 Bausch Health Companies Inc.
23.6.1 Business Overview
23.6.2 Bausch Health Companies Inc. in Global Genital Herpes Treatment Market
23.6.3 Product Offerings
23.6.4 Key Strategies
23.6.5 Key Strengths
23.6.6 Key Opportunities
24 Other Prominent Vendors
24.1 Avet Pharmaceuticals
24.1.1 Business Overview
24.1.2 Product Offerings
24.2 Aurobindo Pharma
24.2.1 Business Overview
24.2.2 Product Offerings
24.3 Abbott
24.3.1 Business Overview
24.3.2 Product Offerings
24.4 Adley Formulations
24.4.1 Business Overview
24.4.2 Product Offerings
24.5 Centurion Remedies
24.5.1 Business Overview
24.5.2 Product Offerings
24.6 Cipla
24.6.1 Business Overview
24.6.2 Product Offerings
24.7 Dr. Reddy's Laboratories
24.7.1 Business Overview
24.7.2 Product Offerings
24.8 Eli Lilly and Company
24.8.1 Business Overview
24.8.2 Product Offerings
24.9 Fdc Limited
24.9.1 Business Overview
24.9.2 Product Offerings
24.10 Finecure Pharmaceuticals Limited
24.10.1 Business Overview
24.10.2 Product Offerings
24.11 Hetero
24.11.1 Business Overview
24.11.2 Product Offerings
24.12 Macleods Pharmaceuticals
24.12.1 Business Overview
24.12.2 Product Offerings
24.13 Medico Remedies Limited
24.13.1 Business Overview
24.13.2 Product Offerings
24.14 Pfizer Inc.
24.14.1 Business Overview
24.14.2 Product Offerings
24.15 Torrent Pharma
24.15.1 Business Overview
24.15.2 Product Offerings
24.16 Zeelab Pharmacy
24.16.1 Business Overview
24.16.2 Product Offerings
24.17 Zydus Group
24.17.1 Business Overview
24.17.2 Product Offerings
25 Report Summary
25.1 Key Takeaways
25.2 Strategic Recommendations
26 Quantitative Summary
26.1 Drug Type
26.1.1 North America: Drug Type Segmentation
26.1.2 Europe: Drug Type Segmentation
26.1.3 Apac: Drug Type Segmentation
26.1.4 Latin America: Drug Type Segmentation
26.1.5 Middle East & Africa: Drug Type Segmentation
26.2 Distribution Channel
26.2.1 North America: Distribution Channel
26.2.2 Europe: Distribution Channel
26.2.3 Apac: Distribution Channel
26.2.4 Latin America: Distribution Channel
26.2.5 Middle East & Africa: Distribution Channel
26.3 Virus Type
26.3.1 North America: Virus Type Segmentation
26.3.2 Europe: Virus Type Segmentation
26.3.3 Apac: Virus Type Segmentation
26.3.4 Latin America: Virus Type Segmentation
26.3.5 Middle East & Africa: Virus Type Segmentation
26.4 Route of Administration
26.4.1 North America: Route of Administration Segmentation
26.4.2 Europe: Route of Administration Segmentation
26.4.3 Apac: Route of Administration Segmentation
26.4.4 Latin America: Route of Administration Segmentation
26.4.5 Middle East & Africa: Route of Administration Segmentation
26.5 Geography
26.5.1 Acyclovir: Geography Segmentation
26.5.2 Valacyclovir: Geography Segmentation
26.5.3 Famciclovir: Geography Segmentation
26.5.4 Other Drugs: Geography Segmentation
26.5.5 Retail Pharmacies: Geography Segmentation
26.5.6 Hospital Pharmacies: Geography Segmentation
26.5.7 Online Pharmacies: Geography Segmentation
26.5.8 Hsv-2: Geography Segmentation
26.5.9 Hsv-1: Geography Segmentation
26.5.10 Oral: Geography Segmentation
26.5.11 Topical: Geography Segmentation
26.5.12 Injection: Geography Segmentation
27 Appendix
27.1 Abbreviations

Companies Mentioned

  • GlaxoSmithKline
  • Glenmark pharmaceuticals
  • Viatris
  • Novartis
  • Teva Pharmaceuticals
  • Bausch Health Companies
  • Reddy's Laboratories
  • Cipla
  • Pfizer
  • Eli Lilly & Company
  • Avet Pharmaceuticals
  • Aurobindo Pharma
  • Centurion Remedies
  • Abbott
  • Macleods Pharmaceuticals
  • FDC
  • Hetero
  • Zydus Group
  • Torrent Pharma
  • Finecure Pharmaceuticals
  • ADLEY FORMULATIONS
  • Medico Remedies
  • Zeelab Pharmacy

Methodology


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.



 

Loading
LOADING...